What Are Beta-Glucans? The Most Important Compound in Medicinal Mushrooms

Bioactive Compounds in Mushrooms

Trained immunity

Beta-glucans from ordinary white button mushrooms can train human immune cells — a lasting shift in how they respond to later threats. A 2024 study found this using grocery-store mushroom powder, though the effect was modest next to yeast-derived beta-glucans.

Case et al., Frontiers in Nutrition, 2024

Dectin-1

the best-characterised beta-glucan receptor — crystal structures resolved by Brown et al., 2007

Contested

whether triple-helix conformation is required for activity — the primary sources here disagree

7+ days

how long beta-glucan-trained protection persisted in mice, transferable via macrophages alone (Stothers, 2021)

Case et al., Frontiers in Nutrition, 2024

View as image ↗

In 2024, researchers tested whether white button mushrooms — the ones at every grocery store — could train immune cells. They could. Powdered Agaricus bisporus drove trained immunity in mouse macrophages and human monocytes, and the effect tracked the amount of available beta-glucan in the powder. The same paper also reported something the headline version usually drops: the response was modest compared with training by yeast-derived beta-glucans, and the trained cells were particularly sensitive to a receptor other than the one most explainers name.^[16]

That pairing — a real effect alongside a messier mechanism — is the honest shape of the beta-glucan story.

Beta-glucans are the primary immune-active compounds in medicinal mushrooms. They are long-chain polysaccharides (glucose polymers) built on a specific backbone: beta-1,3 bonds connecting glucose units along the main chain, with beta-1,6 bonds forming branches. Immune cells recognise this pattern through several receptors, the best-characterised being Dectin-1, and that recognition activates macrophages, natural killer cells, and dendritic cells. In some settings it also leaves a durable imprint on innate immune programming — trained immunity.

This article covers what beta-glucans are structurally, how immune cells recognise them, what trained immunity does and does not establish, what human clinical trials show, and why not all beta-glucans are equivalent. It also flags, throughout, where the popular account outruns the evidence — because on this topic it frequently does.

What Beta-Glucans Actually Are: The Structure That Determines Everything

A beta-glucan is a polymer made of glucose molecules. The key is not what the units are (glucose is glucose) but how they are connected.

In mushrooms, the backbone consists of glucose units linked at their 1 and 3 positions — hence beta-1,3-glucan. Branches extend from this backbone via 1,6 linkages. The result is a branched-chain molecule: a long spine of glucose with shorter glucose branches attached at intervals.

This structure is distinct from the alpha-glucans found in starchy foods, where glucose units are linked at 1,4 and 1,6 positions with a different bond geometry. The alpha versus beta distinction is not a naming convention. It changes the physical shape of the molecule and whether immune receptors engage it at all.

The foundational structure-activity work is a 1995 study by Okazaki and colleagues, which compared several gel-forming beta-1,3-glucans for their ability to induce cytokine production from macrophages.^[1] Its conclusions are more specific — and more surprising — than they are usually reported. The authors found that cytokine release was induced "only by beta-glucans with high molecular weights and lower branching ratios." Native SSG, a very high molecular weight glucan, did not induce cytokine production at all; chemically removing its side branches created that activity.

This matters because the opposite claim is common. Highly branched beta-glucans are frequently described as more immunostimulating than less branched ones. Okazaki's data point the other way, at least in this macrophage system. Branching density clearly modulates the response — but the direction is not the simple "more branches, more activity" rule that supplement marketing tends to assume.

The Triple Helix Question: Contested, Not Settled

The glucose backbone of beta-1,3-glucan does not stay a linear chain under biological conditions. It folds into a triple helix — three strands winding around each other, held by hydrogen bonds.

Nearly every popular explainer treats this conformation as the required basis for biological activity. The primary literature cited in this article does not support that framing.

Unsettled · What Actually Makes a Beta-Glucan Active?

Three Primary Sources, Three Different Answers

The triple helix is routinely described as a settled requirement for beta-glucan bioactivity. The primary literature cited in this article does not support that framing. Each position is reproduced below in the authors’ own words.

Helix shape did NOT matter

Okazaki et al. (1995)

Gel-forming (1→3)-β-D-glucans · mouse macrophages · TNF-α

Comparing naturally occurring triple-helix against single-helix forms, the authors reported no difference in cytokine induction. In this system molecular weight and branching ratio drove the response — and lower branching, not higher, went with more activity.

“The ultrastructure of gel-forming (1→3)-β-D-glucans, especially the triple- and single-helix, does not affect the cytokine-inducing activity.”

Okazaki 1995 [1]

Helix shape DID matter

Falch et al. (2000)

Scleroglucan · human monocytes · TNF-α

Destroying the triple helix with strong alkali irreversibly reduced cytokine-inducing activity. But re-annealing produced material that looked like the original under electron microscopy and the activity still did not return — which complicates a pure "shape causes activity" reading.

“The dose-dependent ability to activate monocytes to cytokine production was not restored following annealing of the denatured-renatured samples, despite the fact that electron micrographs revealed similar structures of these annealed samples to the starting material.”

Falch 2000 [2]

Shape drives signalling, not binding

Anaya et al. (2023)

Candida β-(1,3;1,6)-glucan · Dectin-1A · live-cell imaging

The sharpest modern result splits two things usually treated as one. Structured and unstructured glucans bound Dectin-1 about equally well; only the structured ones triggered signalling. The receptor clusters that formed were small — a few engaged receptors, under 15 nm.

“Glucan denaturation experiments showed that glucan structure determines agonistic potential, but not receptor binding affinity.”

Anaya 2023 [15]

How to hold all three

These studies used different glucans, different responder cells, and different ways of altering conformation. Okazaki compared naturally occurring helix forms; Falch chemically destroyed the helix with alkali, which changes more than shape. Anaya’s split between binding and signalling is the most likely reconciliation: shape may not decide whether a glucan is recognised, but it appears to decide whether recognition turns into a signal. The defensible reading today is that higher-order structure matters for potency in some systems, that the evidence is genuinely mixed, and that no single structural feature has been shown to be the master switch.

Sources: Okazaki et al., Biological & Pharmaceutical Bulletin (1995) [ref 1]; Falch et al., Carbohydrate Research (2000) [ref 2]; Anaya et al. (2023) [ref 15]

The disagreement is real and worth sitting with. Okazaki compared naturally occurring triple- and single-helix forms and reported that the difference did not affect cytokine-inducing activity.^[1] Falch and colleagues, five years later, denatured the triple helix of scleroglucan with strong alkali and found an irreversible reduction in cytokine-inducing activity.^[2]

Note the word reduction, not elimination. And note the detail that complicates the clean story: when Falch's team re-annealed the denatured samples, electron micrographs showed structures resembling the original material — but the biological activity did not return. If shape alone determined activity, restoring the shape should have restored the function. It did not. Alkaline treatment evidently changes something beyond conformation.

Anaya and colleagues, in 2023, drew the distinction that probably reconciles the field.^[15] Working with Candida beta-glucans and live-cell imaging of Dectin-1, they found that structured and unstructured glucans bound the receptor with similar affinity — but only the structured ones triggered signalling. In their words, glucan structure "determines agonistic potential, but not receptor binding affinity."

Structure

Is the triple helix required for beta-glucan activity?

The claim

“Beta-glucan must hold its triple helix conformation to work. Lose the helix and the molecule is biologically inert.”

A widely repeated simplification of Falch et al. (2000), whose title states that cytokine-stimulating activity is dependent on triple helix conformation.

What research shows

Overstated

Falch reported an irreversible reduction in activity after alkaline denaturation — not inertness. Okazaki et al. (1995) compared triple- and single-helix forms directly and reported no effect on cytokine induction at all.

Anaya et al. (2023) suggests why both can be true: structure appears to govern whether Dectin-1 signals, not whether it binds. Higher-order structure plausibly matters for potency in some systems, but no study here establishes it as a required master switch — and re-annealing Falch's samples restored their appearance without restoring their function.

Okazaki et al., 1995 [1]; Falch et al., 2000 [2]; Anaya et al., 2023 [15]

The practical implication survives the correction, in softer form: harsh processing is associated with lost activity in at least one careful study, so extraction quality plausibly affects whether a beta-glucan does anything. But "this product retains its triple helix" is not a claim any consumer can verify, and it is not the settled determinant of potency it is marketed as.

For a deep dive on how the 1,3/1,6 structure relates to bioactivity in practice, see 1,3/1,6 Beta-D-Glucan: Structure, Function, and Health Effects.

The Dectin-1 Switch: How Immune Cells Recognise Beta-Glucan

The immune system does not recognise beta-glucan as "mushroom compound." It recognises it as a pattern associated with fungal cell walls.

Several receptors are involved. Reviews of the field consistently list Dectin-1 alongside complement receptor 3 (CR3, also called CD11b/CD18), lactosylceramide, selected scavenger receptors, and TLR-2/6.^[3][6] Dectin-1 gets the most attention because it is the best understood, not because it is the only route — a distinction that becomes important later in this article.

In 2007, Brown and colleagues reported several crystal structures of Dectin-1, including a 2.8-ångström structure with a short natural beta-glucan trapped in the crystal lattice.^[4] The extracellular domain is a C-type lectin-like domain. Their in vitro work with the natural ligand indicated higher-order complex formation between Dectin-1 and beta-glucans — an early structural hint that the receptor does not act alone.

That hint was confirmed with modern imaging. Anaya's 2023 work watched Dectin-1 aggregate in real time and found the degree of aggregation tracked how structured the glucan was.^[15] Two details deserve emphasis because they are routinely inflated. The clusters were small — "relatively small (<15 nm) clusters of a few engaged receptors," not the large signalling platforms often described. And aggregation increased at fungal particle contact sites in proportion to how much glucan was exposed on the particle surface, which means surface accessibility matters as much as the molecule itself.

From Receptor Binding to Immune Activation

When Dectin-1 engages structured beta-glucan and aggregates, it initiates intracellular signalling that reaches the nucleus and changes gene expression. Goodridge, Wolf, and Underhill reviewed this recognition-to-response translation in 2009, noting that neutrophils, macrophages, and dendritic cells all express receptors capable of recognising beta-glucan in its various forms, and that Dectin-1 is the receptor whose signalling is best characterised.^[7]

The downstream picture is less linear than a single cascade diagram suggests. Mata-Martínez and colleagues, reviewing Dectin-1 signalling in 2022, describe "a plethora of downstream signaling pathways, with complex interrelationships," modulated by factors including phosphatases and tetraspanins.^[14] Critically, the outcomes run in both directions: Dectin-1 engagement produces pro-inflammatory responses such as cytokine production, reactive oxygen species generation, and phagocytosis — but tolerant, regulatory responses have also been attributed to it, depending on which ligand is engaged.

That bidirectionality is the mechanistic basis for calling beta-glucans immune modulators rather than immune stimulants. Akramiene and colleagues established this framing in 2007, describing beta-glucans as biological response modifiers that increase host defence by activating the complement system and enhancing macrophage and natural killer cell function.^[3]

Akramiene also details the most specific anti-tumour mechanism in this literature. Tumour cells, unlike microorganisms, lack beta-glucan as a surface component, so they cannot trigger CR3-dependent cellular cytotoxicity on their own. When antibodies opsonise tumour cells with the complement fragment iC3b, the presence of beta-glucan can supply the second signal that CR3-bearing cells need to kill them.^[3] This is a two-signal mechanism, and it explains why beta-glucan is studied as an adjunct to antibody and chemotherapy regimens rather than as a standalone agent.

Lee and Kim, reviewing fungal beta-glucan innate immunity in 2014, traced how this connects to adaptive immunity: innate cells binding beta-glucan activate B and T lymphocytes and natural killer cells by secreting cytokines including IL-4, IL-6, and TNF-alpha.^[8] They also report a structural finding with direct practical relevance: water-insoluble beta-glucans have stronger immunostimulating activities than their water-soluble counterparts.

There is a gut-level step this cascade depends on and that mechanism diagrams usually omit. Chan and colleagues describe it: after oral administration, the beta-1,3 backbone cannot be digested, so most beta-glucans reach the proximal small intestine intact, where some are captured by macrophages, internalised, fragmented, and transported to the marrow and reticuloendothelial system. The smaller fragments are eventually released and taken up by other immune cells.^[6] Oral beta-glucan does not enter the bloodstream as an intact immune signal; it is couriered.

For more on how this connects to cancer outcomes, see Medicinal Mushrooms in Cancer Treatment: A Complete Guide.

Trained Immunity: The Strongest Finding with the Least Settled Mechanism

The mechanisms above describe what happens while beta-glucan is present. Trained immunity is what happens after it is gone.

Trained immunity is a form of immune memory that does not use antibodies or T cells. Innate immune cells — primarily macrophages and monocytes — are functionally and metabolically reprogrammed so that they respond more vigorously to future threats, including threats they have never encountered.

Trained Immunity

Stothers et al. (2021) · Journal of Immunology

Population

Mice challenged with Pseudomonas aeruginosa; mouse bone marrow-derived macrophages

Intervention

Beta-glucan pre-treatment; separately, adoptive transfer of trained macrophages into naive mice

Comparator

Untrained controls

Finding

Beta-glucan increased recruitment of innate leukocytes to the infection site and improved local bacterial clearance, an effect persisting more than 7 days. Transferring trained macrophages into naive mice conferred comparable protection. Trained macrophages showed enhanced phagocytosis and reactive oxygen species production, alongside sustained increases in glycolytic and oxidative metabolism, mitochondrial mass, and membrane potential.

positive Animal study. Notably, induction of the trained phenotype was independent of the classic beta-glucan receptors Dectin-1 and TLR-2 — a direct complication of the standard mechanistic account.

The Stothers result is strong evidence that beta-glucan training is real, durable, and carried by macrophages themselves — the adoptive transfer experiment is the clean demonstration of that.^[12] But its receptor finding is rarely quoted, and it should be. The trained phenotype did not require Dectin-1.

This sits awkwardly beside Mata-Martínez and colleagues' 2022 review, which positions Dectin-1 as crucial for the initiation of trained immunity.^[14] That review is candid about the state of knowledge: understanding of the complexity in beta-glucan-induced trained immunity, it says, "is still scarce."

The Case 2024 study brought the phenomenon into dietary territory.^[16] Researchers used various powdered forms of white button mushroom — not pharmaceutical extracts. Mouse macrophages pre-treated with whole mushroom powder showed enhanced responses on restimulation, and the effect correlated with available beta-glucan content. Enriching beta-glucan by simulated digestion retained the effect; chemical fractionation boosted it. Both preparations trained human monocytes as well. Mice given the powder by oral gavage showed shifts in bone-marrow progenitor dynamics toward myeloid commitment, and macrophages derived from those mice showed enhanced restimulation responses.

Two qualifications belong with that result. The trained response was modest compared with training by yeast-derived beta-glucans. And the trained cells were particularly sensitive to TLR-2 stimulation — again pointing away from a Dectin-1-only account.

Evidence Reach · Trained Immunity

What Each Source Established — and What It Complicates

Trained immunity is the strongest part of the beta-glucan story. It is also where the tidy “beta-glucan → Dectin-1 → lasting immunity” chain comes apart under its own citations.

Stothers et al. (2021)

Stothers 2021 [12]

Mouse macrophages · Pseudomonas aeruginosa challenge

Established

Beta-glucan training is real and durable in differentiated macrophages: protection persisted beyond 7 days, and transferring trained macrophages into naive mice conferred comparable protection. Trained cells showed enhanced phagocytosis, more reactive oxygen species, higher glycolytic and oxidative metabolism, and increased mitochondrial mass.

Complicates

The training did not run through the receptor the popular account depends on.

“Induction of the trained phenotype was independent of the classic β-glucan receptors Dectin-1 and TLR-2.”

Mata-Martínez et al. (2022)

Mata-Martínez 2022 [14]

Review · Dectin-1 signalling

Established

Dectin-1 recognises beta-glucans and a range of other ligands, and the review positions it as crucial for initiating trained immunity. Downstream outcomes are diverse — cytokine production and phagocytosis, but also tolerant, regulatory responses depending on which ligand is engaged.

Complicates

The review itself flags how much of the mechanism is still unknown.

“The understanding of the above-mentioned complexity in the β-glucan-induced trained immunity is still scarce.”

Case et al. (2024)

Case 2024 [16]

White button mushroom powder · mouse and human myeloid cells

Established

Ordinary Agaricus bisporus powder trained mouse macrophages and human monocytes, and oral dosing in mice shifted bone-marrow progenitors toward myeloid commitment. Enriching the beta-glucan content — by simulated digestion or chemical fractionation — retained or boosted the effect.

Complicates

The size of the effect, and the receptor it leaned on, both cut against the usual framing.

“This trained response was modest compared to training observed with yeast-derived β-glucans ... being particularly sensitive to Toll-like receptor (TLR)-2 stimulation.”

The defensible reading

That beta-glucans induce durable, transferable innate immune training is well supported. Which receptor carries that signal is not settled — one review calls Dectin-1 crucial for initiation while the most detailed macrophage study found training without it, and the mushroom study points at TLR-2. Trained immunity is best described as a robust phenomenon with a contested mechanism, not as a finished pathway.

Sources: Stothers et al., Journal of Immunology (2021) [ref 12]; Mata-Martínez et al., Frontiers in Immunology (2022) [ref 14]; Case et al., Frontiers in Nutrition (2024) [ref 16]

The defensible summary: beta-glucans induce durable innate immune training, this has been shown for ordinary dietary mushrooms as well as purified preparations, and the receptor pathway responsible is not settled.

What Human Clinical Trials Actually Show

The evidence above is largely from cell and animal studies. Here is what controlled trials in humans found.

A 2021 systematic review by Vlassopoulou and colleagues screened 917 records and included 34 randomised controlled trials of oral fungal beta-glucans.^[13] Sources included Saccharomyces cerevisiae, Aureobasidium pullulans, Pleurotus ostreatus, Lentinula edodes, and Ganoderma lucidum, at doses from 2.5 to 1000 mg daily for up to 6.5 months.

What the review found:

• Immunomodulation was the primary outcome across most trials, producing strengthened immune defence that reduced the incidence and symptoms of colds, flu, and other respiratory infections
• Allergic symptoms improved
• Participants reported improved mood states and overall wellbeing
• Beta-glucans showed potential usefulness as a complementary agent for patients undergoing cancer therapy, and for reducing obesity-associated comorbid conditions in overweight adults
• No adverse event causally related to glucans was recorded

And the qualification the review states plainly: findings on the induction of immune response alterations "were inconsistent at the cellular and molecular levels." Clinical symptoms improved more reliably than the immune markers that are supposed to explain them. The review's own conclusion calls for more studies to confirm additional effects, establish optimal dose, and reveal underlying mechanisms.

Beta-Glucans and Immune Function

1. Cell studiescompleted

   Extensive. Receptor structures, signalling, and structure-activity relationships characterised — though with genuine disagreement about which structural features matter.

2. Animal studiescompleted

   Strong. Durable protection from bacterial challenge, transferable by macrophage adoptive transfer (Stothers 2021).

3. Human RCTscompleted

   34 RCTs reviewed, doses 2.5–1000 mg daily. Reduced respiratory infection incidence and symptoms; well tolerated.

4. Large definitive RCTsmissing

   Optimal dose is not established. Cellular and molecular immune findings were inconsistent across trials.

5. Quantitative meta-analysismissing

   Methodological diversity has prevented pooled statistical analysis in the cancer-adjuvant literature (Steimbach 2021).

The clinical signal for reduced respiratory infection is reasonably consistent and the safety record is clean. What is missing is dose optimisation, mechanistic confirmation in humans, and pooled quantitative analysis.

Vlassopoulou et al., 2021 [13]; Steimbach et al., 2021 [11]; Stothers et al., 2021 [12]

For cancer specifically, a 2021 systematic review by Steimbach and colleagues compiled clinical trials using fungal beta-glucans as adjuvants in patients undergoing cancer treatment.^[11] From 1018 articles they retained 16 trials covering 1650 patients across nine cancer types, published between 1992 and 2018, using yeast, Lentinula edodes, Schizophyllum commune, and undescribed fungal sources.

Their findings were genuinely mixed. Administration was safe and well tolerated. Most trials indicated that giving beta-glucan alongside chemotherapy or radiotherapy reduced the immune depression those treatments cause and accelerated recovery of white blood cell counts. But the review also notes that some studies found no statistical difference between beta-glucan and control groups, "which gives a controversial conclusion about the beta-glucan effects." The diversity of study methods and insufficient reporting prevented meaningful pooled statistics, so the authors produced a narrative report and concluded that further evidence is required to determine efficacy.

Chan and colleagues had reached a similar verdict years earlier, noting that no good-quality clinical trial data was then available on the effectiveness of purified beta-glucans among cancer patients, and calling for well-designed trials.^[6]

Immune-Active Compound

Moderate

Beta-glucans modulate immune signalling — some people should check with a clinician first

Concern

Beta-glucans act on innate immune signalling, and Dectin-1 engagement can produce pro-inflammatory or regulatory responses depending on context. That makes their effect in autoimmune disease, in transplant recipients on immunosuppressants, and during active immunotherapy difficult to predict from the general literature.

What the research says

The 34-RCT systematic review recorded no adverse event causally related to glucans, and the 16-trial cancer-adjuvant review found administration safe and well tolerated in 1650 patients. The safety record in studied populations is good.

Particularly relevant for: People with autoimmune conditions, transplant recipients, those on immunosuppressive or immunomodulatory therapy, and anyone undergoing active cancer treatment

What to do

Talk to your oncologist or specialist before adding a beta-glucan supplement to an existing treatment regimen. This article is educational and is not medical advice.

Vlassopoulou et al., 2021 [13]; Steimbach et al., 2021 [11]; Mata-Martínez et al., 2022 [14]

Why Mushroom Beta-Glucans Are Different from Oat and Yeast

The term "beta-glucan" appears on supplement labels for oats, yeast, and mushrooms. These are not the same compound.

Oat beta-glucans use a mixed-linkage 1,3/1,4 backbone with no 1,6 branches. This structure is water-soluble, forms viscous gels in the gut, and has well-documented cardiovascular benefits through cholesterol reduction. Dectin-1 is specific for beta-1,3-linked glucans, so oat beta-glucan is not a Dectin-1 agonist in the way fungal 1,3/1,6 glucans are. The cholesterol effect and the immune effect are different mechanisms in different tissues, and evidence for one is not evidence for the other.

Yeast beta-glucans share the 1,3/1,6 architecture with mushrooms. Here the popular framing tends to invert the evidence. Vetvicka and colleagues compared three glucans across two administration routes and two animal models in 2008, and the yeast-derived preparation was the standout: it significantly stimulated phagocytic activity, potentiated release of IL-1, IL-2, IL-4, IL-6, IL-8, IL-13, and TNF-alpha, inhibited tumour cell growth in vivo, and altered gene expression in breast cancer cells.^[5] They also observed that young and adult animals differed in sensitivity to glucan action.

Case 2024 points the same direction from the mushroom side: training by whole mushroom powder was modest compared with yeast-derived beta-glucans.^[16]

Sources

Are mushroom beta-glucans more immune-active than yeast beta-glucans?

The claim

“Mushroom beta-glucans are the superior immune activators; yeast beta-glucan is the cheap substitute.”

A reasonable-sounding inference from the fact that mushroom and yeast glucans differ in branching frequency and molecular weight.

What research shows

Unsupported

The two head-to-head comparisons in this article's reference list favour yeast. Vetvicka et al. (2008) found a yeast-derived glucan produced significant phagocytic and cytokine stimulation and inhibited tumour growth in vivo. Case et al. (2024) reported that mushroom powder training was modest compared with yeast-derived beta-glucans.

This does not make yeast glucan better for every purpose — the comparisons used specific preparations, doses, and models, and De Marco Castro et al. (2021) caution that human evidence for yeast beta-glucans is weaker than the pre-clinical evidence. The honest position is that source superiority is unestablished in either direction.

Vetvicka et al., 2008 [5]; Case et al., 2024 [16]; De Marco Castro et al., 2021 [10]

A 2021 review by De Marco Castro, Calder, and Roche surveyed yeast-derived beta-1,3/1,6-glucans as immunomodulators, covering both the pre-clinical mechanism work and the newest human trials.^[10] Their conclusion is a useful calibration point for this entire field: baker's-yeast beta-1,3/1,6-glucan may offer increased immunosurveillance according to pre-clinical studies, but "much uncertainty still exists," and the human evidence is weaker than the pre-clinical evidence.

Does Molecular Weight Matter? The Data Are Not a Clean Curve

Molecular weight is often presented as having an optimal window, with a specific range quoted as the target for immune activity. The primary sources here do not support a single window, and they do not even agree on the direction.

Okazaki's 1995 data found that TNF-alpha release correlated with molecular weight for grifolan, with the highest molecular weight fraction (Mr ≥ 45,000) showing the strongest activity — yet native SSG, at Mr ≥ 2,000,000, induced no cytokine production at all until it was debranched.^[1] Molecular weight mattered, but not independently of branching.

Falch's 2000 scleroglucan data describe something closer to a U-shape than a peak: triple-helical samples with weight-average molecular weight below roughly 500,000 g/mol or above roughly 1,100,000 g/mol stimulated monocytes more efficiently than samples in the 670,000–1,100,000 range.^[2] That is the inverse of a simple optimal-window model — the middle of the range performed worst.

Jin, Li, and Wang's 2018 review surveys beta-glucans as immunoadjuvants and the receptors that recognise them, including Dectin-1, CR3, CD5, and lactosylceramide, and covers structure-activity relationships across sources.^[9] It is a useful map of the receptor landscape. It is not the source of a validated numerical molecular-weight window, and no such consensus window exists in the sources reviewed here.

What can be said: molecular weight, branching ratio, solubility, and higher-order structure all modulate potency; they interact; and commercial supplements disclose essentially none of them. For a detailed breakdown of the branching question, see Beta-Glucan 1,3/1,6 Branching: Why Mushroom Beta-Glucans Outperform Oat and Yeast. For the molecular weight analysis, see Beta-Glucan Molecular Weight and Biological Activity: Does Size Matter?.

Which Mushrooms Have the Most Beta-Glucans?

This is the question buyers most want answered, and it is where the published numbers are weakest.

Beta-glucan content varies by species, growing conditions, and which part of the fungus is used. The quantitative reference work in this article's source list is Mirończuk-Chodakowska and colleagues (2017), who measured total beta-glucan and specifically 1,3/1,6-beta-D-glucan across eight wild-growing edible Polish species plus cultivated Agaricus bisporus for comparison.^[18]

Measured · What the Analytical Source Actually Contains

Beta-Glucan by Species, as Measured

These are the anchor values reported in the quantitative reference study for this article. Note which species are present — and which popular ones are not.

Plums-and-custard Tricholomopsis rutilans

40.9 g/100 g

Total beta-glucan · Highest total beta-glucan measured in the study

Portobello Agaricus bisporus

13.5 g/100 g

Total beta-glucan · Lowest total beta-glucan measured — the cultivated comparison species

Wood ear Auricularia auricula-judae

16.8 g/100 g

1,3/1,6 fraction · Highest 1,3/1,6-beta-D-glucan content measured

Cremini Agaricus bisporus

3.9 g/100 g

1,3/1,6 fraction · Lowest 1,3/1,6-beta-D-glucan content measured

Share of total beta-glucan that is 1,3/1,6 linked

Gyroporus cyanescens

54%

Suillus granulatus

49.8%

Auricularia auricula-judae

47.9%

Suillus variegatus

40.6%

Even in the best-performing species, roughly half the measured beta-glucan is not 1,3/1,6 linked — the fraction most associated with immune signalling.

What is missing from this dataset

Reishi, lion’s mane, chaga and oyster mushroom were not measured in this study. It analysed eight wild-growing edible Polish species plus cultivated Agaricus bisporus. Percentage ranges for the popular medicinal species circulate widely and are often credited to analytical work like this, but they do not come from it. Treat any species-level beta-glucan figure as unverified until you can see the assay method and the sample it was run on.

Source: Mirończuk-Chodakowska et al. (2017), quantitative evaluation of 1,3/1,6 beta-D-glucan contents in wild-growing edible Polish mushrooms [ref 18]. Values are g per 100 g dry mass.

Mean total beta-glucan ranged from 13.5 g per 100 g dry mass in A. bisporus (portobello) to 40.9 g per 100 g in Tricholomopsis rutilans. The 1,3/1,6 fraction specifically — the linkage type most associated with immune signalling — ranged from 3.9 g per 100 g in A. bisporus (cremini) to 16.8 g per 100 g in Auricularia auricula-judae, the wood ear mushroom. The species with the greatest proportion of 1,3/1,6 glucan relative to total beta-glucan were Gyroporus cyanescens (54%), Suillus granulatus (49.8%), Auricularia auricula-judae (47.9%), and Suillus variegatus (40.6%). Wild species generally carried more 1,3/1,6 glucan than the cultivated comparison.

That last ratio finding is the practically important one, and it is widely missed. Even in the best-performing species, roughly half of the measured beta-glucan was not 1,3/1,6 linked. A total beta-glucan number on a label is therefore an upper bound on the immune-relevant fraction, not a measure of it.

Note what this dataset does not contain: reishi, lion's mane, chaga, and oyster mushroom were not measured in it. Percentage ranges for those species circulate widely and are often presented as analytical reference values, but they are not traceable to this study. Treat any species-level beta-glucan percentage as unverified unless you can see the assay method and the specific sample it was run on.

Two species-specific points do hold up. Turkey tail (Trametes versicolor) and shiitake (Lentinus edodes) yield beta-glucan fractions — PSK/PSP and lentinan respectively — that have been isolated and used as pharmaceutical agents; their clinical evidence comes from those purified compounds, not from whole mushroom powder. And chaga (Inonotus obliquus) is primarily characterised by melanins and betulinic acid derivatives rather than by beta-glucan content, so a chaga product's rationale does not rest on its beta-glucan number.

Reading a Beta-Glucan Percentage: The Alpha-Glucan Tell

When a mushroom supplement's Certificate of Analysis shows a beta-glucan percentage, the number comes from a subtraction assay. McCleary and Draga published the validated method for mushrooms and mycelial products in 2016.^[17]

The method works in two measurements. Total glucan (plus free glucose and glucose from sucrose) is measured using controlled acid hydrolysis with sulphuric acid, with released glucose quantified by a glucose oxidase/peroxidase reagent. Alpha-glucan — starch and glycogen — plus free and sucrose-derived glucose is measured separately after glucoamylase hydrolyses starch and glycogen and invertase hydrolyses sucrose. Beta-glucan is the difference between the two.

A proper COA therefore shows three numbers: total glucan, alpha-glucan, and beta-glucan. The alpha-glucan column is the one most buyers ignore, and it is the most informative.

Alpha-glucan is starch. In a pure fruiting body product, alpha-glucan should be low — mushrooms do not store significant starch. High alpha-glucan indicates grain in the product, the characteristic signature of mycelium-on-grain preparations where mycelium is grown on a grain substrate and dried with it. The beta-glucan figure on such a COA may be technically accurate while describing a mixture of fungal material and grain starch.

There is a methodological wrinkle that matters when comparing products. McCleary's team compared several acid and enzyme-based hydrolysis options and found sulphuric acid the best. For most samples, sulphuric and hydrochloric acid procedures gave similar values — but for certain samples, specifically Ganoderma lucidum and Poria cocos, the sulphuric acid procedure returned significantly higher values. Assays based entirely on enzymatic hydrolysis generally yielded much lower values than the sulphuric acid procedure.^[17]

The consequence is direct: two reishi products can report different beta-glucan percentages because their labs used different hydrolysis chemistry, not because the mushrooms differ. A percentage without a stated method is not comparable to another percentage without a stated method.

A COA that reports only "polysaccharides" is not using this method at all. Polysaccharides is a broader category including alpha-glucans and other sugars — it is not equivalent to beta-glucans, and the difference is where label inflation happens.

For a step-by-step guide to reading a mushroom supplement COA, see How to Test for Beta-Glucans in Mushroom Supplements. For applying this to purchasing decisions, see How to Choose a Mushroom Supplement: The Science-Based Buyer's Guide.

Beta-Glucans Among Mushroom Bioactives: What They Do Not Cover

Beta-glucans are the best-characterised and most clinically studied mushroom compounds, but they are not the only biologically active fraction.

Reishi contains triterpenes (ganoderic acids) with liver-protective and anti-inflammatory properties. Lion's mane contains hericenones and erinacines, small molecules studied for nerve growth factor stimulation. Chaga contains melanins and betulinic acid derivatives. Turkey tail and shiitake contain polysaccharide-protein complexes (PSK and lentinan) that behave differently from raw beta-glucan in clinical settings.

Understanding beta-glucans gives a foundation for the most important class of mushroom compounds. But mushroom chemistry is multi-compound, and attributing a whole product's effects to its beta-glucan percentage is its own kind of error. For the companion compounds, see Mushroom Triterpenes: The Bitter Compounds with Powerful Effects and Hericenones and Erinacines: Lion's Mane's Brain-Boosting Compounds.

The Bottom Line

Beta-glucans are the primary immune-active compounds in medicinal mushrooms: polysaccharides with a beta-1,3 backbone and beta-1,6 branches that immune cells recognise through Dectin-1, complement receptor 3, and several other receptors. That recognition activates macrophages, NK cells, and dendritic cells, and can produce durable trained immunity. The mechanism is less settled than commonly presented: the primary sources disagree about whether triple-helix conformation is required, one 1995 study found lower branching ratios went with more activity, and the strongest trained-immunity study found the effect independent of Dectin-1. In humans, a review of 34 RCTs found fungal beta-glucans well tolerated with reduced respiratory infection incidence, though immune findings were inconsistent at the cellular level, and the cancer-adjuvant literature reaches no pooled conclusion. Species-level beta-glucan percentages for popular medicinal mushrooms are largely untraceable to analytical sources, and assay chemistry alone can shift a reported percentage.

Frequently Asked Questions

What are beta-glucans in mushrooms?

Beta-glucans are long-chain polysaccharides (glucose polymers) found in mushroom cell walls, built on a beta-1,3 glucose backbone with beta-1,6 branches. They are the primary immune-active compounds in medicinal mushrooms. Immune cells recognise them through several receptors — Dectin-1 is the best characterised, alongside complement receptor 3, lactosylceramide, and TLR-2/6 — and that recognition activates macrophages, natural killer cells, and dendritic cells. In some settings beta-glucans also induce trained immunity, a lasting change in innate immune cell programming.

How do beta-glucans work in the body?

Taken orally, beta-glucans are not digested; they reach the small intestine intact, where macrophages capture and fragment them and transport the fragments to the marrow and reticuloendothelial system for release to other immune cells (Chan et al., 2009). Structured beta-glucan engaging Dectin-1 causes the receptor to aggregate into small clusters, which initiates signalling that changes gene expression — producing cytokines, reactive oxygen species, and phagocytosis, though also regulatory responses depending on the ligand (Mata-Martínez et al., 2022). Beta-glucans can additionally induce trained immunity, but the receptor responsible is unsettled: Stothers et al. (2021) found trained macrophage protection that was independent of both Dectin-1 and TLR-2.

Which mushrooms have the most beta-glucans?

Honest answer: reliable comparative data across the popular medicinal species is thinner than the internet suggests. The quantitative study most often cited measured eight wild-growing edible Polish species plus cultivated Agaricus bisporus — not reishi, lion's mane, chaga, or oyster. In that dataset, total beta-glucan ranged from 13.5 g per 100 g dry mass in portobello to 40.9 g per 100 g in Tricholomopsis rutilans, and the immune-relevant 1,3/1,6 fraction ranged from 3.9 to 16.8 g per 100 g, highest in wood ear (Mirończuk-Chodakowska et al., 2017). Percentage ranges quoted for reishi, lion's mane and chaga should be treated as unverified unless the assay method and sample are disclosed.

Are mushroom beta-glucans better than oat beta-glucans?

They do different things. Oat beta-glucans use a mixed-linkage 1,3/1,4 backbone with no 1,6 branches, are water-soluble, and have well-documented cardiovascular benefits through cholesterol reduction. Dectin-1 is specific for beta-1,3-linked glucans, so oat beta-glucan is not a Dectin-1 agonist in the way fungal 1,3/1,6 glucans are. For immune activation, the fungal 1,3/1,6 structure is the relevant one — but the cardiovascular evidence for oat and the immune evidence for fungal glucans are separate literatures, and neither transfers to the other.

What percentage beta-glucan should a mushroom supplement have?

There is no evidence-based target percentage, and anyone quoting one precisely is going beyond the published data. What is checkable: whether the Certificate of Analysis reports total glucan, alpha-glucan, and beta-glucan separately rather than just "polysaccharides"; whether it states the hydrolysis method, since sulphuric acid, hydrochloric acid, and enzymatic assays can return substantially different values for the same sample (McCleary and Draga, 2016); and whether alpha-glucan is low, since high alpha-glucan indicates grain substrate rather than fruiting body. Method transparency is a more useful signal than the headline percentage.

Do beta-glucans actually boost the immune system?

"Modulate" is more accurate than "boost" — Dectin-1 engagement can produce pro-inflammatory or regulatory responses depending on context. A systematic review of 34 randomised controlled trials found oral fungal beta-glucans reduced the incidence and symptoms of colds, flu and respiratory infections, improved allergic symptoms and mood, and recorded no adverse events causally related to glucans — but also found that effects on immune markers were inconsistent at the cellular and molecular level (Vlassopoulou et al., 2021). For cancer patients, a review of 16 trials in 1650 patients found beta-glucans safe and generally helpful for recovering white blood cell counts after chemotherapy, while noting some trials showed no difference from control and describing the overall conclusion as controversial (Steimbach et al., 2021). This is educational information, not medical advice.

Sources & References

1. 1RTHM-00017·Okazaki, M et al. (1995). “Structure-activity relationship of (1-->3)-beta-D-glucans in the induction of cytokine production from macrophages, in vitro..” Biological & pharmaceutical bulletin.Study breakdown →PubMed →↩
2. 2RTHM-00032·Falch, B H et al. (2000). “The cytokine stimulating activity of (1-->3)-beta-D-glucans is dependent on the triple helix conformation..” Carbohydrate research.Study breakdown →PubMed →↩
3. 3RTHM-00110·Akramiene, Dalia et al. (2007). “Effects of beta-glucans on the immune system..” Medicina (Kaunas.Study breakdown →PubMed →↩
4. 4RTHM-00111·Brown, James et al. (2007). “Structure of the fungal beta-glucan-binding immune receptor dectin-1: implications for function..” Protein science : a publication of the Protein Society.Study breakdown →PubMed →↩
5. 5RTHM-00148·Vetvicka, Vaclav et al. (2008). “Immunological effects of yeast- and mushroom-derived beta-glucans..” Journal of medicinal food.Study breakdown →PubMed →↩
6. 6RTHM-00151·Chan, Godfrey Chi-Fung et al. (2009). “The effects of beta-glucan on human immune and cancer cells..” Journal of hematology & oncology.Study breakdown →PubMed →↩
7. 7RTHM-00154·Goodridge, Helen S et al. (2009). “Beta-glucan recognition by the innate immune system..” Immunological reviews.Study breakdown →PubMed →↩
8. 8RTHM-00333·Lee, Dong Hee et al. (2014). “Innate immunity induced by fungal β-glucans via dectin-1 signaling pathway..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
9. 9RTHM-00513·Jin, Yiming et al. (2018). “β-glucans as potential immunoadjuvants: A review on the adjuvanticity, structure-activity relationship and receptor recognition properties..” Vaccine.Study breakdown →PubMed →↩
10. 10RTHM-01345·De Marco Castro, Elena et al. (2021). “β-1,3/1,6-Glucans and Immunity: State of the Art and Future Directions..” Molecular nutrition & food research.Study breakdown →PubMed →↩
11. 11RTHM-00719·Steimbach, Laiza et al. (2021). “Fungal beta-glucans as adjuvants for treating cancer patients - A systematic review of clinical trials..” Clinical nutrition (Edinburgh.Study breakdown →PubMed →↩
12. 12RTHM-00721·Stothers, Cody L et al. (2021). “β-Glucan Induces Distinct and Protective Innate Immune Memory in Differentiated Macrophages..” Journal of immunology (Baltimore.Study breakdown →PubMed →↩
13. 13RTHM-01451·Vlassopoulou, Marigoula et al. (2021). “Effects of fungal beta-glucans on health - a systematic review of randomized controlled trials..” Food & function.Study breakdown →PubMed →↩
14. 14RTHM-01584·Mata-Martínez, Pablo et al. (2022). “Dectin-1 Signaling Update: New Perspectives for Trained Immunity..” Frontiers in immunology.Study breakdown →PubMed →↩
15. 15RTHM-00814·Anaya, Eduardo U et al. (2023). “Dectin-1 multimerization and signaling depends on fungal β-glucan structure and exposure..” Biophysical journal.Study breakdown →PubMed →↩
16. 16RTHM-00867·Case, Sarah et al. (2024). “β-glucans from Agaricus bisporus mushroom products drive Trained Immunity..” Frontiers in nutrition.Study breakdown →PubMed →↩
17. 17RTHM-00438·McCleary, Barry V et al. (2016). “Measurement of β-Glucan in Mushrooms and Mycelial Products..” Journal of AOAC International.Study breakdown →PubMed →↩
18. 18RTHM-00484·Mirończuk-Chodakowska, Iwona et al. (2017). “Quantitative evaluation of 1,3,1,6 β-D-glucan contents in wild-growing species of edible Polish mushrooms..” Roczniki Panstwowego Zakladu Higieny.Study breakdown →PubMed →↩